Pyruvate Potential Effects on Covid-19 Virus Infection: Novel Fluid Intervention and Prevention

Abstract

Numerous experimental studies demonstrated that Pyruvate is more beneficial than anions in current fluids due to its beneficial biological and pharmacological properties via increasing hypoxia/anoxia tolerance, correcting hypoxic lactic acidosis and exerting anti-oxidative stress, which target against major features of pathological defects in Covid-19 viral infection: hypoxia and cytokine storm. These characteristics indicate that pyruvate is robustly systemic metabolism and multiorgan function protective in critical care patients with or without Covid-19 viral infection. Albeit it is not an anti-virus agent, studies suggest that pyruvate potentially facilitate anti-virus drugs, cytokine IL-6 blockers and interferons against Covid-19 and even inhibit virus replication as chloroquine treated Covid-19. Despite of not FDA-approved, many pyruvate clinical studies with several hundred patients subjected to various diseases strongly support its clinical effectiveness and safety. Currently, pyruvate is a nutritional supplement in markets. It is proposed in this review that compassionate uses of pyruvate-enriched intravenous and oral rehydration solutions are encouraged in intervention and prophylaxis of Covid-19 viral infection.

Citations

Fang-Qiang Zhou. 2023. "Pyruvate Potential Effects on Covid-19 Virus Infection: Novel Fluid Intervention and Prevention". London Journal of Medical and Health Research LJMHR Volume 20 (LJMHR Volume 20 Issue 6): NA.

Related Research

  • Classification

    NLMC CODE: WA 250

  • Version of record

    v1.0

  • Issue date

    NA

  • Language

    English

Iconic historic building with domed tower in London, UK.
Open Access
Research Article
CC-BY-NC 4.0
Request permissions